Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jan Hermen Dannenberg"'
Autor:
Omar Jabado, Suzana Couto, Patricia Coutinho de Souza, Kate Sasser, Mark Fereshteh, Li Fan, Angelo Harris, Arturo Chaparro, Mohammed Qutaish, Han Si, Jan-Hermen Dannenberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6f2d7ef7821f4dcb9279e88c4383277b
Supplementary Fig. S3 from SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule–mediated nuclear factor-κB activation, c-Fos/c-Jun expression, and cellular apoptosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fd78a7b2dfbf4ff59f8a25a0de3f8f2
https://doi.org/10.1158/1535-7163.22485140.v1
https://doi.org/10.1158/1535-7163.22485140.v1
We previously found that the adamantyl-substituted retinoid-related molecules bind to the small heterodimer partner (SHP) as well as the Sin3A complex. In this report, we delineated the role of SHP and the Sin3A complex in 4-[3′-(1-adamantyl)-4′-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::665cc4eb41023b4af01faad038ac2e26
https://doi.org/10.1158/1535-7163.c.6531794.v1
https://doi.org/10.1158/1535-7163.c.6531794.v1
Autor:
Hein te Riele, Jacob B. Hansen, Jan-Hermen Dannenberg, Ji-Ying Song, Sjalin H. Naik, Elly Delzenne-Goette, Anja van der Wal, Sandra de Vries, Marleen Dekker, Kamila Wojciechowicz, Tinke L. Vormer
Supplementary Materials and Methods. Description of additional methods and procedures used in the study. Also includes Supplementary References.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b568b0487b5b696c86f291d2e8fa7c8
https://doi.org/10.1158/0008-5472.22403619
https://doi.org/10.1158/0008-5472.22403619
Autor:
Marinus R. Heideman, Cesare Lancini, Natalie Proost, Eva Yanover, Heinz Jacobs, Jan-Hermen Dannenberg
Publikováno v:
Haematologica, Vol 99, Iss 8 (2014)
Class I histone deacetylases are critical regulators of gene transcription by erasing lysine acetylation. Targeting histone deacetylases using relative non-specific small molecule inhibitors is of major interest in the treatment of cancer, neurologic
Externí odkaz:
https://doaj.org/article/d1d1840bbcd24ee0b5fd6dca65f5f479
Autor:
Jan-Hermen Dannenberg, Kate Sasser, Li Fan, Mark Fereshteh, Han Si, Omar Jabado, Patricia Coutinho de Souza, Mohammed Qutaish, Angelo Harris, Arturo Chaparro, Suzana Couto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with short overall survival; the standard of care (SoC) is chemotherapy. Immunotherapies in development aim to remodel the stroma by depleting immunosuppressive cell types or u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfca8b6cb6e11289c05f979bd4a1b3b4
https://doi.org/10.1136/jitc-2021-sitc2021.928
https://doi.org/10.1136/jitc-2021-sitc2021.928
Autor:
Tessy Korthout, A. F. Maarten Altelaar, Eliza Mari Kwesi-Maliepaard, Liesbeth Hoekman, Sjoerd Hendriks, Sander Palit, Thierry Schmidlin, Heinz Jacobs, Mir Farshid Alemdehy, Jan Hermen Dannenberg, Sjoerd Klarenbeek, Fred van Leeuwen, Cesare Lancini, Tibor van Welsem, Chelsea M. McLean, Hanneke Vlaming, Thom M Molenaar
Publikováno v:
EMBO Journal, 38(14). Nature Publishing Group
The EMBO Journal
EMBO journal, 38(14):e101564. Wiley-Blackwell
The EMBO Journal
EMBO journal, 38(14):e101564. Wiley-Blackwell
DOT1L methylates histone H3K79 and is aberrantly regulated in MLL‐rearranged leukemia. Inhibitors have been developed to target DOT1L activity in leukemia, but cellular mechanisms that regulate DOT1L are still poorly understood. We have identified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::114523b516214375ff4414868b0783ab
https://hdl.handle.net/1874/386558
https://hdl.handle.net/1874/386558
Autor:
Gijs R. van den Brink, Jan Paul Medema, Cesare Lancini, Rachel Sno, Chelsea M. McLean, Hanneke Vlaming, Jan-Hermen Dannenberg, Sanne L. Rosekrans, Cheryl Zimberlin, Michael Bots
Publikováno v:
FASEB journal, 29(5), 2070-2080. FASEB
Histone deacetylases (HDACs) are posttranslational modifiers that deacetylate proteins. Despite their crucial role in numerous biological processes, the use of broad-range HDAC inhibitors (HDACi), has shown clinical efficacy. However, undesired side
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0618460f2f6c73bdde146b48e852e5c2
https://doi.org/10.1096/fj.14-257931
https://doi.org/10.1096/fj.14-257931
Autor:
Cesare Lancini, Heinz Jacobs, Marinus R. Heideman, Jan-Hermen Dannenberg, Natalie Proost, Eva Yanover
Publikováno v:
Haematologica. 99:1292-1303
Class I histone deacetylases are critical regulators of gene transcription by erasing lysine acetylation. Targeting histone deacetylases using relative non-specific small molecule inhibitors is of major interest in the treatment of cancer, neurologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f24eeaff763caee1b658d7d6fb5b1852
https://doi.org/10.3324/haematol.2013.092643
https://doi.org/10.3324/haematol.2013.092643
Autor:
Roel H. Wilting, Jan-Hermen Dannenberg
Publikováno v:
Drug Resistance Updates. 15:21-38
Resistance of cancer cells to chemotherapeutics and emerging targeted drugs is a devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to drug resistance such as increased drug efflux, altered drug metabolism, second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7fd3d434c6e1fb83fab52db3848aa81
https://doi.org/10.1016/j.drup.2012.01.008
https://doi.org/10.1016/j.drup.2012.01.008